<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oncolytic viruses, which preferentially lyse <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and stimulate an antitumor immune response, represent a promising approach to the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, how they evade the antiviral immune response and their selective delivery to, and replication in, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> over <z:mpath ids='MPATH_458'>normal</z:mpath> tissue has not been investigated in humans </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we treated patients with a single cycle of intravenous reovirus before planned surgery to resect <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in the liver </plain></SENT>
<SENT sid="3" pm="."><plain>Tracking the <z:mp ids='MP_0001799'>viral</z:mp> genome in the circulation showed that reovirus could be detected in plasma and blood mononuclear, granulocyte, and platelet cell compartments after infusion </plain></SENT>
<SENT sid="4" pm="."><plain>Despite the presence of neutralizing antibodies before <z:mp ids='MP_0001799'>viral</z:mp> infusion in <z:hpo ids='HP_0000001'>all</z:hpo> patients, replication-competent reovirus that retained cytotoxicity was recovered from blood cells but not plasma, suggesting that transport by cells could protect virus for potential delivery to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of surgical specimens demonstrated greater, preferential expression of reovirus protein in malignant cells compared to either <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stroma or surrounding <z:mpath ids='MPATH_458'>normal</z:mpath> liver tissue </plain></SENT>
<SENT sid="6" pm="."><plain>There was evidence of <z:mp ids='MP_0001799'>viral</z:mp> factories within <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, and recovery of replicating virus from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (but not <z:mpath ids='MPATH_458'>normal</z:mpath> liver) was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> four patients from whom fresh tissue was available </plain></SENT>
<SENT sid="7" pm="."><plain>Hence, reovirus could be protected from neutralizing antibodies after systemic administration by immune cell carriage, which delivered reovirus to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest new preclinical and clinical scheduling and treatment combination strategies to enhance in vivo immune evasion and effective intravenous delivery of oncolytic viruses to patients in vivo </plain></SENT>
</text></document>